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background: Patients with valvular heart disease (VHD) were allowed into the RE-LY® trial if their VHD was considered unlikely to result in an 
intervention before study completion or if prosthetic heart valves or hemodynamically-significant mitral stenosis was present.
methods: The aim of this analysis was to compare RE-LY® patient characteristics and outcomes of dabigatran etexilate (DE) at both doses (150 
mg and 110 mg twice daily) vs warfarin in patients with and without VHD using an interaction p-value.
results: Of the 18,113 patients in RE-LY, 3,950 patients (21.8%) had VHD, as defined by the investigators. The majority (3,101, 17.1%) had mitral 
regurgitation, while 817 (4.5%) had aortic regurgitation, 471 (2.6%) aortic stenosis, 1,179 (6.5%) tricuspid regurgitation and 193 (1.1%) mild mitral 
stenosis. Patients with VHD were older (72.3 vs 71.2 years, p < 0.001) and more likely to have congestive heart failure (39.7% vs 29.8%, p < 0.001), 
coronary artery disease (32.5% vs 26.5%, p < 0.001), moderate renal impairment (creatinine clearance 30 - < 50 mL/min; 22.7% vs 18.2%, p < 
0.001) and higher CHADS2 scores (2.3 vs 2.1, p < 0.01). Compared to patients withoutVHD, patients with VHD had a comparable risk of stroke and 
systemic embolism, but were at higher risk of death and of major bleeding (p ≤ 0.002). However, the relative benefits of DE compared to warfarin 
regarding stroke and systemic embolism (DE 150 mg: hazard ratio [HR] 0.59 [95% CI 0.37, 0.93] with VHD vs 0.67 [0.52, 0.86] without VHD; DE 
110 mg: HR 0.97 (95% CI 0.65, 1.45) with VHD vs. 0.88 [0.70, 1.10] without VHD), major bleeding (DE 150 mg: HR 0.89 [95% CI 0.68, 1.16] with 
VHD vs 0.99 [0.83, 1.17] without VHD; DE 110 mg: HR 0.72 [95% CI 0.54, 0.96] with VHD vs 0.85 [0.71, 1.02] without VHD) and life-threatening or 
intracranial bleeds, were similar in patients with VHD compared to those without (p-values for interaction not significant).
conclusion: Atrial fibrillation patients with valvular heart disease have a higher prevalence of cardiovascular diseases and are at increased risk of 
death and major bleeding, irrespective of assigned anticoagulant treatment. Compared to patients without VHD, they derive similar relative benefits 
of DE over warfarin.
